Global Psoriasis Drugs Market Size, Share, Trends & Growth Analysis Report – Segmented By Drug Type (Pharmaceuticals, Biopharmaceuticals), Route of Administration, Target & Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Industry Analysis From 2026 to 2034
The size of the global psoriasis drugs market is expected to be worth USD 21.86 billion by 2034 from USD 12.44 billion in 2026, growing at a CAGR of 7.30% from 2026 to 2034. The psoriasis drugs market size was valued at USD 11.59 billion in 2025.
Psoriasis is a chronic immune mediated inflammatory skin disorder characterized by the rapid proliferation of keratinocytes leading to the formation of thick silvery scales and itchy dry red patches. The Psoriasis Drugs Market encompasses a broad spectrum of therapeutic interventions ranging from topical corticosteroids and vitamin D analogs to systemic agents and advanced biologic therapies that target specific pathways of the immune system, such as tumor necrosis factor alpha interleukin 17 and interleukin 23. In Europe, alone it is estimated that over 6 million individuals suffer from this debilitating condition which significantly impairs their quality of life. The clinical landscape is evolving with a shift towards personalized medicine where treatment decisions are increasingly based on disease severity patient comorbidities and genetic markers. Recent epidemiological data from the International Federation of Psoriasis Associations indicates that up to 30% of patients with psoriasis develop psoriatic arthritis, which further complicates the therapeutic approach and necessitates multidisciplinary care. The introduction of novel small molecules and biosimilars has expanded the treatment arsenal offering patients more options with improved safety profiles. As understanding of the underlying pathogenesis deepens, the focus has shifted from mere symptom control to achieving complete skin clearance and preventing systemic complications thereby reshaping the therapeutic paradigm and driving innovation in drug development across the continent.
The escalating prevalence of psoriasis due to the chronic and relapsing nature of the disease, which necessitates continuous medical intervention is propelling the growth of the psoriasis drugs market. Epidemiological studies indicate that the incidence of psoriasis is increasing particularly in northern European countries where genetic predisposition and environmental triggers, such as cold climate and low sunlight exposure contribute to higher disease burden. The age standardized prevalence rate of psoriasis in Western Europe has remained stable but the absolute number of cases has risen due to population aging and growth. The older patients often present with more severe forms of the disease and multiple comorbidities, such as cardiovascular disease diabetes and metabolic syndrome, which require complex pharmacological management. The presence of these comorbidities not only exacerbates the clinical course of psoriasis but also limits the use of certain traditional systemic therapies due to safety concerns thereby creating a demand for newer targeted biologics with favorable risk benefit profiles. Furthermore, the recognition of psoriasis as a systemic inflammatory disorder rather than merely a skin condition has led to earlier and more aggressive treatment strategies to prevent long term organ damage.
The rapid advancement in biologic therapies and the emergence of personalized medicine approaches have significantly transformed the treatment through improved clinical outcomes and patient satisfaction, which is another factor accelerating the growth of the psoriasis drugs market. The development of monoclonal antibodies targeting specific cytokines, such as interleukin 17A interleukin 17F and interleukin 23 has revolutionized the management of moderate to severe psoriasis by offering superior efficacy compared to traditional systemic agents. Clinical trials have demonstrated that these newer biologics can achieve PASI 90 and even PASI 100 responses in a substantial proportion of patients, which was previously unattainable with older therapies. According to findings published in the Journal of the American Academy of Dermatology, patients treated with interleukin 23 inhibitors showed sustained skin clearance rates of over 80% after one year of therapy. This high level of efficacy has raised patient expectations and prompted clinicians to adopt these advanced therapies earlier in the treatment algorithm. Moreover, the integration of pharmacogenomics into clinical practice allows for the prediction of individual patient responses to specific drugs thereby minimizing trial and error prescribing and reducing healthcare costs associated with ineffective treatments. The approval of biosimilars for existing biologic agents has also increased accessibility by lowering treatment costs although the initial uptake has been influenced by physician and patient perceptions regarding efficacy and safety. As per the European Medicines Agency, the approval of multiple biosimilars since 2015 has introduced competitive pressure that encourages innovation, while expanding patient access to high quality biological treatments across various healthcare systems in Europe.
The prohibitive cost of biologic therapies, as healthcare systems to balance budget constraints with the need to provide access to high efficacy treatments is limiting the growth of the psoriasis drugs market. Biologic agents often cost between 15000 and 25000 euros per patient annually, which places a substantial financial burden on national health services and insurance providers. According to the Organisation for Economic Co-operation and Development healthcare expenditure on pharmaceuticals in European countries has been rising steadily prompting payers to implement strict reimbursement criteria and step therapy protocols that require patients to fail on cheaper conventional systemic therapies before qualifying for biologics. These restrictive policies delay access to optimal treatment for many patients leading to prolonged disease activity and reduced quality of life. In several southern and eastern European countries, limited healthcare budgets result in uneven access to advanced therapies creating disparities in care standards across the region. The economic evaluation of these drugs often focuses on short term costs rather than long term benefits, such as reduced hospitalizations and improved productivity which hinders favorable reimbursement decisions. The indirect costs associated with untreated or poorly controlled psoriasis, including work absenteeism and presenteeism exceed the direct medical costs yet these factors are frequently overlooked in health technology assessments.
Safety concerns related to long term immunosuppression and the potential for serious adverse events associated with systemic and biologic therapies is declining the growth of the psoriasis drugs market. While biologics have improved safety profiles compared to traditional systemic, agents like methotrexate and cyclosporine they still carry risks of infections malignancies and autoimmune reactions that require vigilant monitoring. According to the European Society of Clinical Microbiology and Infectious Diseases, patients on biologic therapy have a 1.5 to 2 fold increased risk of developing serious infections including tuberculosis and hepatitis B reactivation necessitating pre-treatment screening and ongoing surveillance. This requirement for extensive monitoring adds to the complexity of care and increases healthcare utilization which can deter both physicians and patients from initiating or continuing these treatments. Additionally, the long-term safety data for newer classes of biologics particularly those targeting the interleukin 23 pathway are still being accumulated leading to caution among prescribers, who prefer established therapies with known safety records. The fear of potential malignancies although the absolute risk remains low influences patient willingness to adhere to long term injection based regimens. These safety considerations necessitate careful patient selection and education which can slow the rate of adoption for newer agents and maintain reliance on older less effective but perceived safer treatment options in certain clinical settings.
The expansion of pharmaceutical companies into emerging countries in Central and Eastern Europe, as healthcare infrastructure improves and access to advanced therapies increases is solely to elevate the growth of the psoriasis drugs market in coming years. Countries, such as Poland Romania and Hungary are experiencing economic growth that enables greater investment in healthcare systems including the adoption of innovative medicines. The harmonization of regulatory standards with the European Medicines Agency facilitates faster approval and launch of new drugs in these markets reducing the time lag seen in previous years. Furthermore, the rising awareness of psoriasis as a serious systemic disease among both healthcare professionals and patients in these regions is driving demand for more effective treatment options. Patient advocacy groups are playing an increasingly active role in educating the public and lobbying for better access to care which contributes to market expansion. As per the International Psoriasis Council, the establishment of specialized dermatology centers in urban areas of these countries has improved diagnostic accuracy and treatment adherence creating a conducive environment for the introduction of premium priced biologic agents.
The integration of digital health tools and telemedicine into psoriasis care by enhancing patient engagement monitoring and adherence to treatment regimens is additional factor to leverage new opportunities for the growth of the psoriasis drugs market. Digital platforms including mobile applications and remote monitoring devices enable patients to track their symptoms medication usage and triggers in real time providing valuable data to healthcare providers for timely intervention. These digital solutions facilitate better communication between patients and clinicians leading to improved treatment adherence, which is for the success of long term biologic therapies. Poor adherence is a major cause of treatment failure and increased healthcare costs yet digital reminders and educational content can significantly mitigate this issue. Furthermore, the data collected through these platforms can be utilized for real world evidence generation supporting regulatory approvals and reimbursement decisions by demonstrating the effectiveness of drugs in diverse patient populations outside of controlled clinical trials. The adoption of artificial intelligence algorithms in dermatology is improving diagnostic accuracy and personalizing treatment recommendations which enhances patient outcomes and satisfaction.
The complexity of regulatory approvals and the heterogeneity of reimbursement policies is to pose as a major challenge for the growth of the psoriasis drugs market. Each country has its own health technology assessment body with distinct methodologies for evaluating clinical efficacy cost effectiveness and budget impact leading to inconsistent reimbursement decisions. This fragmentation delays patient access to innovative treatments and creates uncertainty for manufacturers regarding return on investment. The requirement for local real-world evidence and comparative effectiveness studies further complicates the launch process requiring substantial resources and time. Additionally, price negotiations are conducted at the national level resulting in wide variations in drug prices across the continent, which can lead to parallel trade issues and supply chain complexities. These disparities create an uneven playing field where patients in wealthier nations gain earlier access to life changing therapies while those in lower income countries face prolonged wait times. The lack of a unified European market for pharmaceutical reimbursement forces companies to navigate a labyrinth of bureaucratic hurdles which increases operational costs and slows down the overall pace of innovation adoption thereby challenging the strategic planning and market entry strategies of global pharmaceutical players.
The patient non-adherence and the significant psychological burden that impacts treatment outcomes is also to decline the growth of the psoriasis drugs market. Even with injectable biologics adherence rates decline over time due to injection fatigue fear of needles and the perceived lack of immediate visible improvement. According to research from the European Journal of Dermatology depression and anxiety affect up to 60% of patients with psoriasis, which further exacerbates non adherence as mental health issues reduce motivation and ability to manage complex treatment regimens. This psychological comorbidity is often underdiagnosed and undertreated leading to a vicious cycle where poor mental health worsens skin symptoms and vice versa. The stigma associated with visible skin lesions also contributes to social isolation and reduced quality of life, which negatively impacts patient engagement with healthcare providers. Pharmaceutical companies face the challenge of developing not only effective drugs but also comprehensive support programs that address the psychosocial aspects of the disease. The lack of integrated care models that combine dermatological and psychological support results in suboptimal treatment outcomes and increased healthcare utilization.
| REPORT METRIC | DETAILS |
| Market Size Available | 2025 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| Segments Analysed | By Drug Type, Route of Administration, Target & Region |
| Various Analyses Covered | Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
| Regions Analysed | North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
| Market Leaders Profiled | Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA). |
The biopharmaceuticals segment was the largest by holding 34.2% of the Psoriasis Drugs Market share in 2025 due to their superior efficacy in treating moderate to severe cases and their ability to target specific immune pathways with precision. The clinical superiority of biologics over traditional small molecule drugs in achieving complete skin clearance. The significant difference in therapeutic outcome has shifted clinical guidelines globally to recommend biologics as first line treatments for severe disease. Furthermore, the expanding patent landscape for interleukin inhibitors has broadened the treatment options available to clinicians. As per the European Medicines Agency over 15 distinct biologic agents are currently approved for psoriasis treatment in Europe providing a robust portfolio that addresses various patient needs and resistance patterns. The high barrier to entry for biosimilars also protects the revenue streams of innovator companies allowing for sustained investment in research and development. Additionally, the long acting nature of many biologics which require administration only once every few weeks or months improves patient compliance compared to daily oral medications.
The biopharmaceuticals segment is esteemed to grow at a fastest CAGR of 12.5% from 2026 to 2034 owing to the continuous introduction of novel mechanisms of action that offer improved safety profiles and higher efficacy rates. The increasing approval of interleukin 23 inhibitors, which have demonstrated unprecedented durability in maintaining skin clearance. According to clinical data published in The Lancet, patients treated with interleukin 23 inhibitors maintained PASI 90 response rates of over 75% for up to five years without significant loss of efficacy. This long term durability reduces the need for switching therapies and enhances patient satisfaction. Biosimilars are projected to save healthcare systems in Europe approximately 10 billion euros by 2026, thereby increasing accessibility to biologic treatments for a broader patient population. The strategic partnerships between pharmaceutical companies and healthcare providers to facilitate early access programs also accelerate adoption.
The topical administration segment was accounted in holding 34.8% of the psoriasis drugs market share in 2026. The majority of patients manage their condition with topical corticosteroids vitamin D analogs and combination therapies due to their favorable safety profile and ease of use. These agents provide localized relief with minimal systemic absorption thereby reducing the risk of adverse events associated with oral or injectable treatments. The widespread availability of generic topical formulations further enhances accessibility and affordability by making them the cornerstone of psoriasis management in both developed and emerging markets. As per data from the International Psoriasis Council topical therapies are prescribed in over 90% of initial consultations reflecting their entrenched position in clinical practice. Moreover, advancements in formulation technology such as foams sprays and ointments have improved patient compliance by addressing issues related to messiness and application difficulty. The chronic nature of psoriasis necessitates long term maintenance therapy for which topicals are well suited due to their flexibility in dosing and ability to be used intermittently.
The oral administration segment is likely to grow at a fastest CAGR of 9.8% from 2026 to 2034 owing to the introduction of novel small molecule drugs, such as phosphodiesterase 4 inhibitors and Janus kinase inhibitors which offer the convenience of oral dosing with efficacy comparable to some biologics. The patient preference for non-injectable treatments, which eliminates the fear of needles and the need for clinical visits for administration. According to a survey conducted by the National Psoriasis Foundation over 60% of patients expressed a strong preference for oral medications over injectables due to convenience and ease of use. The approval of apremilast and deucravacitinib has expanded the therapeutic arsenal for patients, who are ineligible for or resistant to biologics. As per clinical trial data published in the New England Journal of Medicine deucravacitinib demonstrated superior efficacy compared to apremilast and placebo achieving PASI 75 responses in 58% of patients at week 16. This robust clinical performance has encouraged clinicians to prescribe oral agents earlier in the treatment algorithm. Additionally, the lower cost of oral small molecules compared to biologics makes them an attractive option for healthcare payers seeking to control expenditures. The expanding label indications for these drugs to include difficult to treat areas such as the scalp and nails further drives adoption.
The interleukin inhibitors segment was the largest by holding 44.3% of the psoriasis drugs market share in 2025 due to their exceptional efficacy and safety profile, which has redefined the standard of care for moderate to severe psoriasis. The superior performance of interleukin 17 and interleukin 23 inhibitors in achieving rapid and sustained skin clearance. According to meta analyses published in JAMA Dermatology, interleukin 17 inhibitors achieve PASI 90 responses in approximately 75% of patients within 12 weeks, which is significantly higher than tumor necrosis factor inhibitors. This high level of efficacy has made interleukin inhibitors the preferred choice for clinicians treating patients with severe disease burden. Furthermore, the long dosing intervals associated with interleukin 23 inhibitors which range from 8 to 12 weeks enhance patient adherence and quality of life. The safety profile of these agents is also favorable with lower rates of serious infections compared to older biologics. The continuous innovation in this space with the introduction of dual inhibitors targeting multiple interleukin pathways further strengthens their market position. Pharmaceutical companies are heavily investing in this segment with numerous pipeline candidates focusing on novel interleukin targets.
The interleukin inhibitor segment is likely to witness a fastest CAGR of 14.2% from 2026 to 2034 with the ongoing shift in treatment paradigms towards higher efficacy benchmarks, such as PASI 100 or complete skin clearance. The increasing recognition of the importance of treating psoriasis, as a systemic inflammatory disease where controlling skin symptoms is linked to improved cardiovascular and metabolic outcomes. The patients achieving complete skin clearance with interleukin inhibitors show significant reductions in markers of systemic inflammation, such as C reactive protein. This holistic benefit drives prescribing behavior among multidisciplinary teams. The expansion of the patient population eligible for these therapies due to improved safety data in special populations including elderly patients and those with comorbidities. The launch of next generation interleukin 23 inhibitors with even longer half lives and higher potency further accelerates growth. Additionally, the competitive pricing strategies employed by manufacturers to gain market share from established tumor necrosis factor inhibitors stimulate uptake. The combination of superior clinical outcomes broadening eligibility and strategic commercial efforts positions interleukin inhibitors as the most rapidly expanding segment in the psoriasis drugs market.
North America was the top performer of the global Psoriasis Drugs Market by accounting for 45.3% share in 2025 due to its high healthcare expenditure advanced medical infrastructure and early adoption of innovative therapies. The favorable reimbursement environment for high cost biologic therapies, which encourages the use of premium priced drugs. According to the Centers for Disease Control and Prevention approximately 7.5 million adults in the United States have psoriasis by creating a substantial patient base for pharmaceutical interventions. The presence of major pharmaceutical companies and research institutions in the region fosters continuous innovation and rapid commercialization of new drugs. The approval timeline for new psoriasis treatments in the United States is among the shortest globally allowing patients quicker access to cutting edge therapies. The high prevalence of obesity and metabolic syndrome in the population, which are known exacerbating factors for psoriasis further drives demand for effective treatments. Additionally, the strong influence of patient advocacy groups ensures that psoriasis remains a priority in healthcare policy and funding decisions. The integration of digital health solutions and telemedicine platforms also enhances patient engagement and adherence contributing to market growth. The competitive landscape is characterized by aggressive marketing strategies and patient support programs offered by key players to maintain brand loyalty.
Europe psoriasis drugs market held second position by holding 30.3% of the share in 2025 with a heterogeneous with varying levels of access to advanced therapies, across different countries. Germany, France, and the United Kingdom, are the key contributors to market revenue due to their well-established healthcare systems and high diagnosis rates. The aging population in Europe is a significant driver as the prevalence of psoriasis increases with age. The region also benefits from strong regulatory frameworks enforced by the European Medicines Agency, which ensure the safety and efficacy of new treatments. The prevalence of psoriasis in Northern Europe is among the highest globally due to genetic and environmental factors driving consistent demand for therapeutic interventions. The increasing adoption of biosimilars in countries like Sweden and Denmark is reshaping the market dynamics by reducing costs and improving accessibility. Furthermore, the emphasis on personalized medicine and precision healthcare in European clinical guidelines promotes the use of targeted biologics. The presence of renowned dermatology centers and research networks facilitates the conduct of clinical trials and the dissemination of best practices.
The Asia Pacific psoriasis drugs market is likely to grow at a fastest CAGR in coming years with increasing healthcare awareness and improving economic conditions. China, India, and Japan, are the primary markets within this region contributing to its expansion. The prevalence of psoriasis in Asia is estimated to be lower than in Western countries but the absolute number of patients is high due to the large population base. The rising disposable income and expanding middle class, which enables greater spending on healthcare services. As per data from the Chinese Society of Dermatology the diagnosis rate of psoriasis in China has increased by 15% annually over the past decade reflecting improved access to dermatological care. The government initiatives in countries like India to improve healthcare infrastructure and insurance coverage are also facilitating market growth. The entry of international pharmaceutical companies into these markets through partnerships and local manufacturing agreements enhances product availability. Furthermore, the increasing prevalence of lifestyle related comorbidities such as diabetes and hypertension which are associated with psoriasis drives the need for comprehensive management strategies. The growing awareness of the psychological impact of psoriasis among younger demographics also contributes to higher treatment seeking behavior.
Latin America Psoriasis Drugs Market growth is likely to grow with the improving healthcare access and increasing awareness of autoimmune diseases. Brazil, Mexico, and Argentina, are the leading countries in this region contributing to market expansion. The prevalence of psoriasis in Latin America is comparable to global averages but underdiagnosis remains a significant challenge. The gradual improvement in public healthcare systems and the expansion of private insurance coverage which enhances access to biologic therapies. The involvement of patient advocacy groups in raising awareness and lobbying for better reimbursement policies is also stimulating the market growth. Additionally, the increasing prevalence of obesity and metabolic disorders in the region which are risk factors for psoriasis drives demand for therapeutic interventions. The entry of generic manufacturers and the potential introduction of biosimilars are expected to reduce costs and improve accessibility in the near future.
The Middle East and Africa psoriasis drugs market growth is driven by the limited access to advanced therapies and varying healthcare infrastructure. The prevalence of psoriasis in the Middle East is influenced by genetic factors and high rates of consanguinity, which may increase susceptibility. The government investment in healthcare modernization and the adoption of international treatment guidelines is also fuelling the growth of the market. The establishment of specialized dermatology clinics has improved diagnosis and treatment outcomes driving demand for modern therapies. In Africa the lack of trained dermatologists and essential medicines remains a barrier but initiatives by global health organizations are aiming to improve capacity. The increasing awareness of psoriasis as a chronic condition requiring long term management is slowly changing patient behavior.
The competition in the psoriasis drugs market is intense and characterized by rapid innovation and frequent product launches. Major pharmaceutical companies compete fiercely to establish dominance through superior efficacy and safety profiles of their biologic and small molecule therapies. The entry of biosimilars has further intensified price competition forcing innovator companies to differentiate their products through enhanced patient services and digital health integration. Strategic collaborations and licensing agreements are common as firms seek to expand their pipelines and access new technologies. Regulatory approvals in multiple jurisdictions are critical for maintaining competitive advantage and ensuring global market access. Companies invest heavily in clinical trials to generate robust real world evidence that supports reimbursement negotiations and physician adoption. The focus on personalized medicine and precision therapeutics allows players to target specific patient segments more effectively. Patent expirations of blockbuster drugs create opportunities for generic manufacturers while prompting innovators to develop next generation treatments.
Companies that are playing a promising role in the global psoriasis drugs market include
AbbVie Inc
AbbVie Inc maintains a formidable presence in the psoriasis treatment landscape through its robust portfolio of biologic therapies including Skyrizi and Humira. The company focuses heavily on research and development to expand indications and improve patient outcomes for moderate to severe plaque psoriasis. Recent strategic initiatives include launching new formulation options and dosing regimens that enhance patient convenience and adherence. AbbVie actively engages in real world evidence generation to demonstrate long term efficacy and safety profiles to healthcare providers and payers. The company also invests in digital health platforms to support patient management and education. Their commitment to innovation is evident in ongoing clinical trials exploring novel mechanisms of action.
Amgen Inc
Amgen Inc plays a pivotal role in the psoriasis market with its flagship product Otezla and other innovative immunology assets. The company emphasizes scientific excellence to develop targeted therapies that address unmet medical needs in dermatology. Amgen has recently focused on expanding the reach of its oral treatments by securing approvals in additional geographic regions and indications. Strategic partnerships with healthcare providers aim to improve disease awareness and early diagnosis rates. The company also prioritizes patient support programs that facilitate access to therapy and enhance treatment persistence. Amgen continues to invest in manufacturing capabilities to ensure consistent supply and quality of its biologics. Their recent efforts include collaborating with digital health companies to integrate remote monitoring tools into patient care pathways.
Bristol Myers Squibb
Bristol Myers Squibb contributes significantly to the psoriasis drugs market through its diverse pipeline and established immunology franchise. The company leverages its expertise in small molecule and biologic technologies to offer comprehensive treatment options. Recent actions include advancing late-stage clinical trials for novel inhibitors targeting specific inflammatory pathways involved in psoriasis pathogenesis. Bristol Myers Squibb actively pursues regulatory approvals in key international markets to broaden patient access to its therapies. The company also engages in strategic collaborations with academic institutions to deepen understanding of disease mechanisms and identify new therapeutic targets. Their focus on personalized medicine drives the development of biomarkers that predict patient response to treatment. Additionally, Bristol Myers Squibb implements robust pharmacovigilance programs to monitor safety and maintain trust among clinicians and patients.
Key players in the psoriasis drugs market primarily employ strategies such as mergers and acquisitions to expand their therapeutic portfolios and gain access to novel technologies. Companies frequently engage in strategic partnerships with biotechnology firms to co-develop innovative biologics and small molecules. Product launches of next generation inhibitors targeting interleukin pathways are common to capture market share from older therapies. Pricing strategies including tiered pricing and patient assistance programs are implemented to enhance accessibility in diverse economic environments. Regulatory expansion efforts focus on securing approvals in emerging markets to tap into underserved patient populations. Investment in digital health tools and telemedicine platforms helps improve patient adherence and engagement. Clinical trial expansions into pediatric and special populations broaden the eligible patient base. Biosimilar development is another critical strategy to compete with off patent biologics and reduce costs. Marketing campaigns emphasizing real world evidence and quality of life improvements help differentiate products.
This research report on the global psoriasis drugs market has been segmented and sub-segmented based on drug type, route of administration, target, and region.
By Drug Type
By Route of Administration
By Target
By Region
Frequently Asked Questions
The global psoriasis drugs market size was worth USD 10.80 billion in 2024.
Yes, we have studied and included the COVID-19 impact on the global psoriasis drugs market in this report.
Geographically, the APAC region is expected to register fastest CAGR in the global market during the forecast period.
Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen (USA), and AbbVie (USA) are some of the notable companies in the psoriasis drugs market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region